Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Salsalate + Venetoclax/Decitabine for Patients With Acute Myelogenous Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

NCT04146038 is registered in ClinicalTrials.gov with Rutgers, The State University of New Jersey as lead sponsor.

NCT NCT04146038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04146038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Salsalate + Venetoclax/Decitabine for Patients With Acute Myelogenous Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease
Lead sponsor
Rutgers, The State University of New Jersey
Phase
Phase 2
Overall status
Completed
Start date
October 26, 2020
Completion date
October 25, 2022
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, chronic myelomonocytic leukemia, myeloblasts 10 percent or more of bone marrow nucleated cells, myelodysplastic syndrome, myeloproliferative neoplasm, recurrent acute myeloid leukemia, refractory acute myeloid leukemia, secondary acute myeloid leukemia